Compare Cassava Sciences Inc (FLNA) vs KB Financial Group, Inc. (KB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs KB Financial Group, Inc. — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while KB Financial Group, Inc. trades at $122.32 (market cap $41.90B). The key difference: KB Financial Group, Inc. is far larger — about 788.5× Cassava Sciences Inc's market cap, and KB Financial Group, Inc. pays a 2.58% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | KB | |
|---|---|---|
Market Cap | $53.14M | $41.90B |
Sector | Health | Financials |
52-Week High | $4.64 | $123.25 |
52-Week Low | $1.09 | $77.50 |
Enterprise Value | -$33.43M | — |
Dividend Yield | — | 2.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
KB Financial Group's stock trades at $121.02, showing modest daily gains. The technical outlook is bullish with strong moving average signals, though oscillators are neutral. Fundamentally, the company demonstrates consistent revenue and net income growth, with a trailing P/E of 11.69 and strong net margin of 27.82%. Recent quarterly earnings have consistently beaten expectations, and the company is diversifying into non-banking operations, which now contribute 43% of earnings according to Seeking Alpha (2026-07-09).
The outlook is positive with earnings momentum and strategic diversification providing stability, though risks include potential overbought technical conditions and execution challenges in non-banking expansion. Analyst sentiment is mixed with a 33% buy rating, indicating cautious optimism about the company's growth trajectory and capital distribution plans.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →
